Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)

Bristol-Myers Squibb (BMY) shares dropped 5.8% after its Q2 2025 results revealed a 29.5% year-over-year decline in non-GAAP EPS to $1.46, primarily due to IPRD charges from its BioNTech partnership, leading to a reduced full-year earnings forecast. While reported revenues increased 1% and the growth portfolio for the first time exceeded the legacy portfolio, alongside an upgraded full-year revenue guidance, the significant profit contraction disappointed investors, highlighting a near-term earnings drag from strategic long-term growth investments.

Analysis

Bristol-Myers Squibb's (BMY) Q2 2025 results present a clear dichotomy between its improving long-term revenue outlook and significant near-term earnings pressure, which prompted a 5.8% stock decline. The primary negative catalyst was a 29.5% year-over-year drop in non-GAAP EPS to $1.46, driven by IPRD charges related to a new partnership with BioNTech. Critically, even after adjusting for these charges, underlying EPS still contracted by 2.8%, leading management to reduce full-year EPS guidance by approximately 5.1% at the midpoint. This earnings weakness overshadows several positive strategic developments. For the first time, revenue from the growth portfolio, which grew a robust 17% YoY, surpassed that of the legacy portfolio, which shrank by 13.6%. Furthermore, the company upgraded its full-year revenue forecast for the second time, now anticipating a smaller 2.7% annual contraction versus the 5.8% initially feared. While the stock's valuation appears attractive with a forward P/E of 6.66x and a compelling 5.73% dividend yield, the market is currently prioritizing the immediate earnings drag from strategic investments over the prospective, but not yet realized, benefits of its pipeline transformation.

Key Decisions for Investors

• Value-oriented investors may find the 5.73% forward dividend yield and low 6.66x forward P/E attractive, but must be prepared to endure near-term earnings volatility as the company invests heavily in its future pipeline.
• Given the significant EPS miss and downward revision to earnings guidance, momentum-focused investors should remain cautious until there is clear evidence that profitability is troughing and that revenue improvements are translating to bottom-line growth.
• Investors should closely monitor the revenue ramp-up of the growth portfolio and new products like Cobenfy as key validation points for the long-term strategy, weighing them against future earnings reports to identify the inflection point where strategic investments begin to yield profit accretion.